Drug information of Insulin aspart

Mechanism of effect

The primary activity of Insulin aspart is the regulation of glucose metabolism. binds to the insulin receptor

Pharmacodynamic

Insulin aspart is a rapid-acting insulin analogue used to mimic postprandial insulin spikes in diabetic individuals. The onset of action of insulin aspart is 10-15 minutes. Its activity peaks 60-90 minutes following subcutaneous injection and its duration of action is 4-5 hours

Pharmacokinetics

Rapidly absorbed following subcutaneous administration (more so than regular human insulin). <10% bound to plasma proteins.Half life is 81 minutes (following subcutaneous administration in healthy subjects).clearance is 1.2 L/h/kg [healthy Caucasian male], excreted in the urine

Drug indications

diabetes mellitus type 1 , diabetes mellitus type2

Dosage

Insulin aspart is a short acting insulin with a rapid onset and should be given immediately before meals. 50 to 70% of the daily insulin requirement may be provided by aspart and the remainder by an intermediate or long-acting insulin Insulin dosage should be individualized to achieve/maintain a target blood glucose level and is determined by various factors including body weight, body fat, physical activity, insulin sensitivity, blood glucose levels, and target blood glucose.

Drug contraindications

hypersensitivity to drug or its components. , episodes of hypoglycemia

Side effects

nausea , Headache , Diarrhea , Peripheral edema , diabetic retinopathy , Weight increase , Hypoglycemia , Lipodystrophy

Interactions

Erythromycin , Sirolimus , Glibenclamide , Metolazone , Medroxyprogesterone , Clozapine , Atenolol , Somatropin-Human Growth hormone , Carvedilol , Liraglutide , Pramlintide , Miglitol , Alclometasone , flurandrenolide

Alerts

1- Hypoglycemia is the most common adverse effect of all insulin therapies 2- All insulin products, including Insulin aspart cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia that, if left untreated, may cause respiratory paralysis, ventricular arrhythmia, and death. Use caution in patients who may be at risk for hypokalemia (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations, and patients receiving intravenously administered insulin) 3- As with other insulins, the dose requirements for NovoLog may be reduced in patients with renal impairmen 4- As with other insulins, the dose requirements for NovoLog may be reduced in patients with hepatic impairmen 5- Local Reactions - As with other insulin therapy, patients may experience redness, swelling, or itching at the site of Insulin aspart Injection. These reactions usually resolve in a few days to a few weeks, but in some occasions, may require discontinuation of Insulin aspart

Points of recommendation

1- May be mixed with insulin isophane (NPH), but should be injected immediately. Insulin aspart should be drawn up in to the syringe first. Do not give mixtures IV 2- Do not mix with zinc insulins 3- Do not mix with any other insulins or diluents when using insulin aspart in subcutaneous insulin infusion pumps. 4- Discard insulin if exposed to temperatures higher than 98.6 degrees F (37 degrees C)

Pregnancy level

B